Reports first surfaced in the New York Times earlier this month about problems at a Baltimore, Md., plant run by Emergent BioSolutions, where both the AstraZeneca-Oxford and Johnson & Johnson vaccines were being manufactured. Canada received 300,000 doses this week, Health Canada told CBC News. Health Canada says it remains "confident" the 1.5 million doses of AstraZeneca vaccine imported from the same facility meet quality specifications. 7:34The department previously said the J&J doses Canada was expecting were not coming from the Baltimore plant. "Canadians can be assured that Health Canada is taking all necessary steps to ensure that any products coming from this facility will only be used if they are safe and effective," Health Canada said in a statement on Sunday.

Source: CBC News April 30, 2021 22:57 UTC